Skip to main content

Advertisement

SpringerLink
Log in

The care of patients with chronic kidney disease

What must we do and who should do it?

  • Editorials
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The K/DOQI Clinical Practice Guidelines on Chronic Kidney Disease Work Group. K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Am J Kidney Dis. 2002;39:S1-S266.

    Article  Google Scholar 

  2. U.S. Renal Data System. 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethseda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.

    Google Scholar 

  3. U.S. Renal Data System. 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethseda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.

    Google Scholar 

  4. Jones C, McQuillan G, Kusek J, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998;32:992–9 (erratum: Am J Kidney Dis. 2000;35:178).

    PubMed  CAS  Google Scholar 

  5. Modification of Diet in Renal Disease Study Group. Effects of dietary protein restriction on the progression of moderate renal disease in the MDRD Study. J Am Soc Nephrol. 1996;7:2616–26.

    Google Scholar 

  6. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337–45.

    PubMed  CAS  Google Scholar 

  7. Pereira BJG. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int. 2000;57:351–65.

    Article  PubMed  CAS  Google Scholar 

  8. Winkelmayer WC, Owen Jr W, Glynn RJ, Levin R, Avorn J. Preventive health care measures before and after start of renal replacement therapy. J Gen Intern Med. 2002;17:588–95.

    Article  PubMed  Google Scholar 

  9. Obrador GT, Ruthazer R, Arora P, Kausz A, Pereira BJG. Prevalence of and factors associated with sub-optimal care prior to initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1793–800.

    PubMed  CAS  Google Scholar 

  10. Kasiske B, Vazquez M, Harmon W, et al. Clinical practice guidelines of the American Society of Transplantation: recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1-S86.

    PubMed  Google Scholar 

  11. Standards of Medical Care for Patients with Diabetes Mellitus. Position statement. Clinical practice recommendations. Diabetes Care. 2001;24(Suppl 1):33–43.

    Google Scholar 

  12. Levey A Clinical practice series: non-diabetic kidney disease. N Engl J Med. 2002. In press.

  13. Howard A. Long-term management of the renal transplant recipient: optimizing the relationship between the transplant center and the community nephrologist. Am J Kidney Dis. 2001;38:S1-S55.

    Google Scholar 

  14. Viberti GC, Bilous RW, MacKintosh D, Bending JJ, Keen H. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. BMJ. 1983;286:598–602.

    Article  PubMed  CAS  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.

    Article  PubMed  CAS  Google Scholar 

  16. Laffel LMB, McGill JB, Gans D. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med. 1995;99:497–504.

    Article  PubMed  CAS  Google Scholar 

  17. The Diabetes Control and Complications Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–20.

    Article  Google Scholar 

  18. Parving HH, Andersen AR, Smidt UM, Homel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ. 1987;294:1443–7.

    PubMed  CAS  Google Scholar 

  19. Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension. 1985;7:109–13.

    Google Scholar 

  20. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–84.

    Article  PubMed  CAS  Google Scholar 

  21. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 1976;36:383–88.

    PubMed  CAS  Google Scholar 

  22. Christlieb AR, Warram JH, Krolewski AS, et al. Hypertension: the major risk factor in juvenile-onset insulin-dependent diabetics. Diabetes. 1981;30(Suppl 2):90–6.

    PubMed  CAS  Google Scholar 

  23. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.

    PubMed  CAS  Google Scholar 

  24. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.

    Article  PubMed  CAS  Google Scholar 

  25. Zuchelli P, Zucalla A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452–8.

    Article  Google Scholar 

  26. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833–7.

    PubMed  CAS  Google Scholar 

  27. Brenner B, Cooper M, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  PubMed  CAS  Google Scholar 

  28. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.

    Article  PubMed  CAS  Google Scholar 

  29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

    Article  Google Scholar 

  30. Wang PH, Lau J, Calmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306–9.

    Article  PubMed  CAS  Google Scholar 

  31. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis. 1992;20:533–47.

    PubMed  CAS  Google Scholar 

  32. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996; 124:627–32.

    PubMed  CAS  Google Scholar 

  33. Kasiske BL, Lakatua JDA, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–61.

    PubMed  CAS  Google Scholar 

  34. The K/DOQI Nutrition Work Group. K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000;35(Suppl 2):S56–64.

    Google Scholar 

  35. Khan S, Kazmi H, Abichandani R, Tighiouart H, Pereira B, Kausz A. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62:229–36.

    Article  PubMed  Google Scholar 

  36. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347–54.

    PubMed  CAS  Google Scholar 

  37. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiologic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.

    Article  PubMed  CAS  Google Scholar 

  38. U.S. Renal Data System. USRDS 1997 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997.

    Google Scholar 

  39. Port F. Morbidity and mortality in dialysis patients. Kidney Int. 1994;46:1728–37.

    Article  PubMed  CAS  Google Scholar 

  40. McCusker FX, Teehan BP, Thorpe KE, Keshaviah PR, Churchill DN, for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. How much peritoneal dialysis is required for the maintenance of a good nutritional state? Kidney Int. 1996;50:S56–61.

    Google Scholar 

  41. Churchill D, Taylor D, Cook R, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992;19:214–34.

    PubMed  CAS  Google Scholar 

  42. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61.

    PubMed  CAS  Google Scholar 

  43. Churchill DN, Muirhead N, Goldstein M, et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol. 1995;43:184–8.

    PubMed  CAS  Google Scholar 

  44. Madore F, Lowrie E, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997;8:1921–9.

    PubMed  CAS  Google Scholar 

  45. Xia H, Ebben J, Ma J, Collins A. Hematocrit levels and hospitalization risk in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–16.

    PubMed  CAS  Google Scholar 

  46. Collins AJ, Ma J, Ebben J. Hospital length of stay is associated with hematocrit level. J Am Soc Nephrol. 1997;8:190A.

    Google Scholar 

  47. Locatelli F. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: the experience of Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Tufts-New England Medical Center, Boston, Mass

    Annamaria T. Kausz MD, MS & Andrew S. Levey MD

Authors
  1. Annamaria T. Kausz MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew S. Levey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kausz, A.T., Levey, A.S. The care of patients with chronic kidney disease. J GEN INTERN MED 17, 659–663 (2002). https://doi.org/10.1046/j.1525-1497.2002.20634.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2002.20634.x

Search

Navigation